About CONCORD HC GP Company

US-China Jiahe Medical Technology Development Group Co., Ltd. is China's leading overall solution platform for oncology care. It has long focused on the research, development, transformation and application of advanced cancer diagnosis and treatment technology. Since its establishment, it has attracted many powerful partners and the support of state-owned financial institutions. The US-China Jiahe Group has also received strategic investment from many well-known institutions such as CICC Capital, CITIC Industrial, Shengshan Asset, and Shiyao Group. In the future, it will work with partners as a mixed ownership enterprise to jointly promote the development and transformation of medical services in China. As a national high-tech enterprise, the US-China Jiahe Group is based in the core city of Beishangguang and has laid out, built and operated a number of international medical institutions specializing in oncology throughout the country. At present, the company has formed a complete business system combining online and offline, featuring precise radiotherapy, covering different business segments such as oncology specialist medical institutions, Internet medical care, cloud system solutions that empower third party medical partners with medical and Internet technology, independent imaging center+AI, and science and technology innovation centers focusing on medical technology incubation, transformation, application and output. Currently, the company's main business includes being able to provide patients with a full range of oncology medical services throughout the diagnosis and treatment process, as well as an enterprise customer network that is widely empowered by integrated tumor-related services. Empowering content includes various links in the industry chain, such as oncology diagnosis and treatment solutions, operation management, equipment leasing, and maintenance services. In terms of oncology medical services, the US-China Jiahe Group has 8 self-owned medical institutions in China, including 3 cancer hospitals, 2 clinics, 1 outpatient department, 1 medical imaging diagnosis center, and 1 internet hospital, ranking second in number among social oncology medical groups in China. In order to enable patients to enjoy international high-quality diagnosis and treatment services, the company has introduced international advanced diagnosis and treatment service methods, procedures and management models to its medical institutions, and provided cutting-edge technology and equipped with advanced diagnosis and treatment equipment. This is particularly represented by the proton therapy systems of Guangzhou Taihe Cancer Hospital and Shanghai Taihecheng Cancer Hospital. The US-China Jiahe Group is one of the medical groups with multiple proton therapy systems in China. Its subsidiary Guangzhou Taihe Cancer Hospital is the first mature medical institution with a proton radiotherapy system in South China, equipped with an internationally leading Varian Probeam proton therapy system and a strong medical team composed of well-known experts at home and abroad. Currently, clinical trials of the proton system at Guangzhou Taihe Cancer Hospital are progressing steadily. It is estimated that in the future, the system can treat about 2,000 cancer patients every year, which will greatly promote the development of the health industry in the Guangdong-Hong Kong-Macao Greater Bay Area. In order to accelerate the implementation of international and high-quality oncology medical services in China, the US-China Jiahe Group has taken advantage of its international cooperation resources to carry out in-depth cooperation with the globally recognized top MD Anderson Cancer Center and Miaoyou Healthcare International, which is the most influential in the world and represents the highest medical standards in the world. Since 2015, MD Anderson Cancer Center has been deeply involved in the planning of various aspects of business processes, quality control, and standardized management of Guangzhou Taihe Cancer Hospital, Shanghai Taihecheng Cancer Hospital, and Shanghai Meizhong Jiahe Oncology Clinic. At the same time, its medical institutions have also learned MD Anderson's cutting-edge cancer diagnosis and treatment technology and related quality control agreements and methods. The Shanghai Meizhong Jiahe Oncology Clinic passed the MD Anderson Cancer Center radiotherapy site certification in 2018, indicating that the outpatient department has reached the leading international level in terms of the quality of daily oncology diagnosis and treatment. Since 2020, Miaoyou Medical International has also provided cooperative consulting services related to professional training, process management, and scientific research transformation to Guangzhou Taihe Cancer Hospital, a subsidiary of the Group. Currently, Guangzhou Taihe Cancer Hospital has formulated a complete set of service standards consistent with Miaoyou Medical International, and has also become one of Miaoyou Medical's internationally certified referral centers, which will help more Chinese patients obtain world-class medical services in the future. In order to benefit more patients with high-quality cancer diagnosis and treatment capabilities, standardized models, and internationalization concepts, the US-China Jiahe Group has built an asset-light business model (CSS business) using advanced technology such as cloud computing to empower enterprise customers with cloud-based B2B2C services, especially for medical institution customers located in low-tier cities that cannot be covered by the Group's own medical institutions. Enabling services mainly include remote consultation, radiotherapy quality control, supply chain management, and joint research, training and technical support. The Group launched the “Jiahe Yunying Telemedicine Information Diagnosis Platform” in 2020 and the “Jiahe Feiyun Intelligent Radiotherapy Cloud Platform” in 2021, thereby greatly improving the quality of cancer diagnosis and treatment for institutional customers in low-tier cities and contributing to alleviating the unequal distribution of medical resources for cancer diagnosis and treatment in China. In August 2021, the “Jiahe Yunying Telemedicine Information Diagnosis Platform” and the “Jiahe Feiyun Intelligent Radiotherapy Cloud Platform” were shortlisted for 5G+ healthcare application pilot projects organized by the Ministry of Industry and Information Technology and the National Health and Health Commission. With outstanding performance, the CSS business has developed rapidly. As of June 8, 2023, 51 medical institutions have completed the listing of 5G healthcare pilot units. The US-China Jiahe Group has strong technical strength in the field of radiation therapy, thus laying a solid foundation for the development and expansion of the CSS business. Among the 15 guideline projects approved by the National Cancer Center Radiation Therapy Quality Control Expert Committee announced by the National Cancer Center in June 2020, the “Whole Body Irradiation Technology Practice Guide” project hosted by an expert team from the US and China Jiahe Group is listed. This is the first guideline project approved by a private medical institution in China. The guidelines were released on May 28, 2023. In addition, the “Radiation Therapy Data Review Quality Assurance Practice Guidelines” and “Guidelines for the Design, Implementation and Quality Control Platform Construction of 5G-based Remote Radiotherapy Plans” declared by the US-China Jiahe Group in February 2022 have also been approved by the National Oncology Quality Control Center.